ESR1 and breast cancer: As a selective estrogen receptor modulator (SERM) with antagonistic properties in the breast and paradoxically agonistic functions in the uterine endometrium, bone, and cardiovascular system, tamoxifen is administered in both pre- and postmenopausal BC patients [3,7].